Timothy Springer Buys $101,967 in Cartesian Therapeutics Shares By Investing.com
In a recent move, Timothy A. Springer, a director and major shareholder…
CEL-SCI Reports Positive Bias Analysis on Cancer Therapeutics Provided by Investing.com
VIENNA, Va. – CEL-SCI Corporation (NYSE American: CVM) announced the results of…
Rapport Therapeutics Director Buys $9.5 Million in Company Stock By Investing.com
James Healy, Director of Rapport Therapeutics, Inc. (NASDAQ:RAPP), recently purchased a significant…
